E
EXELIXIS INC
NASDAQ: EXEL (Exelixis, Inc.)
Last update: 1 hour ago70.70
0.12 (0.17%)
| Previous Close | 70.58 |
| Volume | 2,229,709 |
| Price / Earnings (Forward) | 16.68 |
| Price / Sales | 7.48 |
| Price / Book | 9.42 |
| 52 Weeks Range |
| Profit Margin | 27.99% |
| Operating Margin (TTM) | 33.64% |
| Diluted EPS (TTM) | 2.19 |
| Quarterly Revenue Growth (YOY) | 30.60% |
| Quarterly Earnings Growth (YOY) | 327.70% |
| Total Debt/Equity (MRQ) | 8.78% |
| Current Ratio (MRQ) | 3.50 |
| Operating Cash Flow (TTM) | 842.59 M |
| Levered Free Cash Flow (TTM) | 559.13 M |
| Return on Assets (TTM) | 18.05% |
| Return on Equity (TTM) | 30.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Exelixis, Inc. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| EXEL | - | - | - | 9.42 |
| TERN | 6 B | - | - | 6.08 |
| TRML | 1 B | - | - | 4.76 |
| IVVD | - | - | - | 0.930 |
| ARVN | - | - | - | 0.860 |
| ABEO | - | - | - | 1.11 |
AIStockmoo Score
| Value 35% | 4.8 |
| AI Insight info | NA |
| Relative Valuation info | 5.0 |
| Financial Health info | 4.5 |
| Timing 35% | 3.4 |
| AI Technical info | NA |
| Technical Oscillators info | 4.0 |
| Technical Moving Averages info | 2.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| News Mood info | NA |
| Environment | ×0.79 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -22.4% |
| Pillar Agreement | ×1.25 |
| Not in score | |
| Price Volatility info | -3.0 |
| Final Score | 2.83 |
Select this tab to load the latest available analysis.
|
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.20% |
| % Held by Institutions | 93.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Farallon Capital Management, L.L.C. | 30 Jun 2026 | 13,468,010 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
Forget clinical cash burns: Why Exelixis is up 38% since June
Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below. |
| 11 Nov 2026 | Yahoo Finance |
Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision Nears
Exelixis (NASDAQ:EXEL) is working to build its next cancer drug franchise around zanzalintinib, or zanza, while continuing to grow its established CABO business, Chief Strategy Officer Andrew Peters said at a conference discussion with Guggenheim biotech analyst Michael Schmidt. Peters described th… |
| 11 Nov 2026 | Yahoo Finance |
Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib
Exelixis (NASDAQ:EXEL) is preparing for a regulatory decision on its cancer drug candidate zanzalintinib and expects results from a kidney cancer study in the first quarter of next year, Chief Strategy Officer Andrew Peters said at an investor event. Peters described the company as approaching a tr… |
| 09 Nov 2026 | Yahoo Finance |
Short Sellers Are Betting Against This Biotech Stock at All-Time Highs, But You Should Still Add it to Your Watchlist
Exelixis (EXEL) demonstrates strong technical momentum, recently hitting a new all-time high. Shares are up more than 70% over the past 52 weeks. EXEL maintains a 100% “Buy” technical opinion from Barchart. Valuation appears stretched, with Morningstar citing 24% overvaluation and high short… |
| 03 Nov 2026 | Yahoo Finance |
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
ALAMEDA, Calif., November 03, 2026--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:… |
| 02 Nov 2026 | Yahoo Finance |
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations
Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. |
| 31 Oct 2026 | Yahoo Finance |
Earnings Beat Could Be A Game Changer For Exelixis Stock (EXEL)
Exelixis reported third quarter 2026 revenue of US$658.7 million and net income of US$218.1 million, with earnings per share above Wall Street expectations and full year revenue guidance maintained at US$2.5b to US$2.55b. The business leaned on its cabozantinib franchise while spotlighting… |
| 31 Oct 2026 | Yahoo Finance |
Exelixis (EXEL) Beats Q3 Estimates, Is The Stock Fully Priced?
Exelixis (EXEL) is back in focus after its third quarter 2026 earnings, where revenue reached US$658.7 million and net income came in at US$218.1 million, both above last year’s levels. The earnings beat and steady 2026 guidance reset the tone around Exelixis, with the share price up 4.82% on the… |
| 30 Oct 2026 | Yahoo Finance |
EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales
Exelixis tops Q3 2026 earnings and revenue estimates as Cabometyx sales grow, share repurchases accelerate and its zanzalintinib pipeline advances. |
| 30 Oct 2026 | Yahoo Finance |
Exelixis, Inc. Q3 2026 Earnings Call Summary
Moby summary of Exelixis, Inc.'s Q3 2026 earnings call… |
| 30 Oct 2026 | Yahoo Finance |
Exelixis (EXEL) Q3 2026 Earnings Call Transcript
Cabozantinib sales grew 11% year over year as zanzalintinib advances toward FDA decisions. |
| 29 Oct 2026 | Yahoo Finance |
Exelixis (EXEL) Surpasses Q3 Earnings and Revenue Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of +5.62% and +0.86%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 29 Oct 2026 | Yahoo Finance |
What Exelixis (EXEL) Said on Its Q3 Earnings Call
Exelixis (NASDAQ:EXEL) reported third-quarter 2026 revenue of approximately $659 million, supported by continued growth in its cabozantinib franchise and progress toward a potential launch of zanzalintinib in colorectal cancer. Chief Executive Officer Mike Morrissey said the company is positioning… |
| 29 Oct 2026 | Yahoo Finance |
Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?
Is EXEL a good stock to buy? We came across a bullish thesis on Exelixis, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on EXEL. Exelixis, Inc.’s share was trading at $66.28 as of October 28th 2026. EXEL’s trailing and forward P/E were 20.62 and 15.25… |
| 29 Oct 2026 | Yahoo Finance |
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
ALAMEDA, Calif., October 29, 2026--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. |
| 29 Oct 2026 | Yahoo Finance |
Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
| 29 Oct 2026 | Yahoo Finance |
Exelixis: Q3 Earnings Snapshot
(EXEL) on Thursday reported third-quarter profit of $218.On a per-share basis, the Alameda, California-based company said it had net income of 85 cents. |
| 27 Oct 2026 | Yahoo Finance |
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 26 Oct 2026 | Yahoo Finance |
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis. |
| Show more | ||
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |